(Q40748761)

23 September 2017

title

Spectrum of use for the angiotensin-receptor blocking drugs (English)

1 reference

23 September 2017

Fabiani ME

1

1 reference

23 September 2017

Johnston CI

series ordinal

2

1 reference

23 September 2017

publication date

1 October 1999

1 reference

Current Hypertension Reports

23 September 2017

published in

1 reference

23 September 2017

volume

1

1 reference

23 September 2017

issue

5

1 reference

23 September 2017

page(s)

394-401

1 reference

https://scigraph.springernature.com/pub.10.1007/s11906-999-0054-1

23 September 2017

exact match

0 references

cites work

Mechanisms of angiotensin II formation in humans

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11906-999-0054-1

Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11906-999-0054-1

Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11906-999-0054-1

Angiotensin II: a pivotal factor in the progression of renal diseases

21 January 2018

1 reference

12 December 2020

Human type 2 angiotensin II receptor gene: cloned, mapped to the X chromosome, and its mRNA is expressed in the human lung

1 reference

12 December 2020

Rationale and pharmacology of angiotensin II receptor antagonists: current status and future issues

1 reference

12 December 2020

Valsartan in heart failure patients previously untreated with an ACE inhibitor

1 reference

12 December 2020

The importance of left ventricular hypertrophy in human hypertension

1 reference

12 December 2020

Molecular cloning of the human angiotensin II type 2 receptor cDNA

1 reference

12 December 2020

Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators

1 reference

12 December 2020

Molecular cloning of the human AT2 receptor.

1 reference

12 December 2020

Irbesartan treatment in hypertension

1 reference

12 December 2020

Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension

1 reference

12 December 2020

Chromosomal assignment of human and rat hypertension candidate genes: type 1 angiotensin II receptor genes and the SA gene

1 reference

12 December 2020

Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study

1 reference

12 December 2020

Effects of losartan on hypertension and left ventricular mass: a long-term study

1 reference

12 December 2020

Angioedema associated with angiotensin II receptor antagonist losartan

1 reference

12 December 2020

Physiological and pharmacological implications of AT1 versus AT2 receptors.

1 reference

12 December 2020

Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension.

1 reference

12 December 2020

Identification of two subtypes in the rat type I angiotensin II receptor

1 reference

12 December 2020

Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension

1 reference

12 December 2020

The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan

1 reference

12 December 2020

The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group

1 reference

12 December 2020

Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies

1 reference

12 December 2020

Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension.

1 reference

12 December 2020

ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema

1 reference

12 December 2020

Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients

1 reference

12 December 2020

Molecular cloning, sequence analysis and expression of a cDNA encoding human type-1 angiotensin II receptor

1 reference

12 December 2020

Angioedema induced by the angiotensin II blocker losartan

1 reference

12 December 2020

Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension

1 reference

12 December 2020

Angiotensin II receptors and angiotensin II receptor antagonists.

1 reference

12 December 2020

Angiotensin II receptors.

1 reference

12 December 2020

An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators

1 reference

12 December 2020

Cloning and characterization of a human angiotensin II type 1 receptor

1 reference

12 December 2020

Hypertension and stroke--rationale behind the ACCESS trial. Acute Candesartan Cilexetil Evaluation in Stroke Survivors.

1 reference

12 December 2020

Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients.

1 reference

12 December 2020

Circulating versus local renin-angiotensin system in cardiovascular homeostasis.

1 reference

12 December 2020

The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design.

1 reference

12 December 2020

Receptors and their classification: focus on angiotensin II and the AT2 receptor

1 reference

12 December 2020

Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension

1 reference

12 December 2020

ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management

1 reference

12 December 2020

Analysis of the evolution of angiotensin II type 1 receptor gene in mammals (mouse, rat, bovine and human)

1 reference

12 December 2020

Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors

1 reference

12 December 2020

Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression

1 reference

12 December 2020

Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension

1 reference

12 December 2020

Angioneurotic edema attributed to the use of losartan

1 reference

12 December 2020

Molecular cloning and sequencing of the gene encoding human angiotensin II type 1 receptor

1 reference

12 December 2020

Valsartan. A review of its pharmacology and therapeutic use in essential hypertension

1 reference

12 December 2020

Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure

1 reference

12 December 2020

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

1 reference

12 December 2020

Candesartan cilexetil. A review of its use in essential hypertension

1 reference

12 December 2020

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

1 reference

12 December 2020

Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors

1 reference

12 December 2020

Localization of the genes encoding the three rat angiotensin II receptors, Agtr1a, Agtr1b, Agtr2, and the human AGTR2 receptor respectively to rat chromosomes 17q12, 2q24 and Xq34, and the human Xq22

1 reference

12 December 2020

Angiotensin II receptor antagonists in hypertension

1 reference

12 December 2020

Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators

1 reference

12 December 2020

Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension

1 reference

12 December 2020

Angiotensin converting enzyme inhibitors in pregnancy

1 reference

12 December 2020

Franz Volhard Lecture. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control

1 reference

12 December 2020

Angiotensin receptors and their therapeutic implications

1 reference

12 December 2020

Renal hemodynamic effects of candesartan in normal and impaired renal function in humans

1 reference

12 December 2020

Comparison of losartan and amlodipine in renally impaired hypertensive patients

1 reference

12 December 2020

Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension

1 reference

12 December 2020

Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues

1 reference

12 December 2020

Chromosomal localization of angiotensin II type 1 receptor isoforms in the rat

1 reference

12 December 2020

Angiotensin-converting enzyme-independent pathways of angiotensin II formation in human tissues and cardiovascular diseases

1 reference

12 December 2020

Molecular Cloning of AT1 Angiotensin Receptors

1 reference

12 December 2020

Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy.

1 reference

12 December 2020

Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension

1 reference

12 December 2020

Dual pathway for angiotensin II formation in human internal mammary arteries

1 reference

12 December 2020

Angioedema and photosensitive rash induced by valsartan

1 reference

12 December 2020

Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components

1 reference

12 December 2020

Angiotensin converting enzyme inhibitors in hypertension: potential problems

1 reference

12 December 2020

A study of losartan, alone or with hydrochlorothiazide vs nifedipine GITS in elderly patients with diastolic hypertension

1 reference

12 December 2020

Role of the angiotensin II AT2-subtype receptors in the blood pressure-lowering effect of losartan in salt-restricted rats

1 reference

12 December 2020

Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996).

1 reference

12 December 2020

Safety of irbesartan in the treatment of mild to moderate systemic hypertension

1 reference

12 December 2020

Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension.

1 reference

12 December 2020

A randomized, double-blind comparison of the antihypertensive efficacy and safety of once-daily losartan compared to twice-daily captopril in mild to moderate essential hypertension

1 reference

12 December 2020

Angiotensin receptor antagonists: focus on losartan

1 reference

12 December 2020

Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study.

1 reference

12 December 2020

Use of losartan in the treatment of hypertensive patients with a history of cough induced by angiotensin-converting enzyme inhibitors.

1 reference

12 December 2020

10.1007/S11906-999-0054-1

Identifiers

DOI

1 reference

23 September 2017

1 reference